Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minoxidil and finasteride have improved hair thickness and density, but temple areas remain stubborn. Continued use is recommended, with suggestions for topical minoxidil, microneedling, or considering a hair transplant for further improvement.

The user experienced increased hair density and thickness after 3-4 months using finasteride, minoxidil, dermastamping, ketoconazole, and biotin. They apply minoxidil right after dermastamping without any side effects or shedding.

Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.

Ultrasound imaging can predict hair shedding and assess hair growth stages by analyzing hair follicle characteristics. The conversation also discusses using ultrasound for personal hair analysis and mentions the potential use of infrared emission for hair treatment.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

Hair transplant recipients are concerned about whether dormant follicles are permanently damaged by incisions, but some believe undamaged follicles could still regrow if a treatment like PP405 is effective. Opinions vary on the impact of transplants on original follicles, with some suggesting treatments like finasteride can help regrow hair.

Beard gains from minoxidil are usually permanent due to facial hair follicles' lower sensitivity to DHT. Scalp hair requires ongoing DHT suppression with treatments like finasteride, dutasteride, and RU58841 to maintain gains after stopping minoxidil.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

The user is pleased with increased hair density and thickness after six months of using topical minoxidil and finasteride. They plan to continue the treatment and consider adding dermarolling for potentially better results.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

Microneedling may enhance hair regrowth by transferring stem cells to dormant follicles, improving the effects of minoxidil. Users discuss using microneedling with needle lengths around 1.5mm to stimulate hair growth.

A user is considering a hair transplant with 3,000 grafts for mid-scalp and crown coverage, but there is skepticism about whether this will provide sufficient density. The user has been using treatments like finasteride and minoxidil for 10 years, which have slowed hair loss.

The user switched from finasteride to dutasteride after initially seeing improved hair density with finasteride, but experienced worsened hair loss and shedding with dutasteride. They are considering switching back to finasteride due to these issues.

A user had a hair transplant of 1000 grafts in the temples and is using finasteride to maintain hair density. The procedure cost $2,200 and was done in Medellín, Colombia.

RepliCel's potential hair loss treatment may cost around $1000 and aims to protect hair follicles from DHT, possibly reversing some miniaturization. It is not considered a cure and may be most effective in early hair loss stages, with its main advantage over finasteride being the lack of sexual side effects.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

A user shared their experience with a beard-to-scalp hair transplant, noting no visible scars and improved hair density using finasteride and minoxidil. The conversation discusses the differences between beard and scalp hair, potential changes in hair texture, and the use of beard hair for increased scalp coverage.

Using finasteride and minoxidil for six months led to improved hair density and appearance. A temporary decrease in libido was noted as a side effect.

UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.

The "DHT itch" is real and likely due to inflammation at the hair follicle, exacerbated by increased testosterone or androgens. Treatments mentioned include dutasteride, minoxidil, finasteride, and various topical solutions.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.

A sugar gel called 2-deoxy-D-ribose (2dDR) shows potential for promoting hair regrowth by increasing blood supply to hair follicles, similar to Minoxidil, but its effectiveness in humans is unproven. It may benefit those who don't tolerate Minoxidil, but it is not a replacement for treatments like Finasteride or RU58841.

Redensyl is discussed as a hair loss treatment, with claims of stopping hair loss and increasing hair density after three months, but users generally believe it is not better than minoxidil. Some users suggest it is comparable to 1% minoxidil, while others dismiss its effectiveness.

Combining Minoxidil with peptide serums like Redensyl, Procapil, and Capixyl is more effective for hair growth than using Minoxidil alone, increasing hair density and thickness. However, some users are skeptical about the effectiveness of peptides, suggesting other ingredients or factors might contribute to the results.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.